New Immune-suppressive Therapy for Graft-versus-host Disease
The FDA approved axatilimab-csfr, an inhibitor of monocytes and macrophages, for certain patients with chronic graft-versus-host disease. The U.S....
Progress Against Cancer
The FDA approved axatilimab-csfr, an inhibitor of monocytes and macrophages, for certain patients with chronic graft-versus-host disease. The U.S....
The FDA has approved vorasidenib to treat certain brain tumors harboring an IDH1 or IDH2 mutation. The U.S. Food...
Afamitresgene autoleucel has received accelerated approval to treat certain patients with synovial sarcoma. The U.S. Food and Drug Administration...
The FDA has approved dostarlimab-gxly plus chemotherapy to treat more patients with endometrial cancer. The U.S. Food and Drug...
The targeted therapy was approved by the FDA for use in combination with bortezomib, lenalidomide, and dexamethasone. The U.S....
The FDA approved the immunotherapy epcoritamab-bysp for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA)...
The FDA issued its first approval for the use of A KRAS G12C inhibitor in a tumor type other...
The FDA approved pembrolizumab, in combination with chemotherapy, for certain patients with endometrial cancer. The U.S. Food and Drug...
The FDA approved the bispecific T-cell engager blinatumomab for use in the consolidation phase of therapy for certain patients...
The immunotherapy durvalumab may be used with chemotherapy to treat certain endometrial cancers. The U.S. Food and Drug Administration...